GLOW blend
Also called GHK-Cu + BPC-157 + TB-500
A three-ingredient research blend promoted for skin quality and recovery. Ingredient research does not show that the combined injectable blend delivers those results in people.
Overview
What it is
One supplier's 70 mg vial contains 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500. That is 70 mg total, not 70 mg of each. "GLOW" is not a standardized formula, so check the label.
How it works
GHK-Cu is a copper peptide studied for collagen and elastin production. BPC-157 is studied in tissue-repair models. TB-500 may mean full-length thymosin beta-4 or a seven-amino-acid fragment depending on the supplier.
What the research shows
A topical GHK-Cu formulation improved wrinkle measures in 40 women over eight weeks; that was a cream, not an injectable blend. BPC-157 improved tendon healing in rats. A 2025 IV safety pilot of BPC-157 included only two people. No study tested GLOW.
Studied for
- Collagen and wrinklestopical GHK-Cu
- Tendon healingBPC-157, rats
Safety and regulatory status
Safety and side effects
No blend-specific side-effect data exist. The FDA has flagged immune-reaction and impurity concerns for BPC-157 and injectable GHK-Cu. Topical tolerability does not establish injectable safety. New symptoms after an injection should not be dismissed as "healing."
Regulatory status
Not FDA approved. BPC-157 and injectable GHK-Cu appear on FDA's list of compounding substances with potential safety risks.
Mixing and dosing reference
Reference information only. Read before using this section.
GLOW (70 mg Blend) Dosage Protocol
- Vial
- 70 mg total blend 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500
- Add diluent
- 3 mL
- Concentration
- 23.33 mg/mL
- 1 unit (U-100)
- 233.33 mcg total in 0.01 mL
- Route
- Subcutaneous
- How often
- Once per day (subcutaneous), at a consistent time preferred.
- Cycle length
- 4 weeks of daily dosing, followed by 2–4 weeks off to evaluate progress and allow receptor resetting.
Standard Approach
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 2,330 mcg | 10 units (0.10 mL) |
How to mix
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall to minimize foaming.
- Gently swirl or roll the vial until fully dissolved (do not shake vigorously).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- Follow a use-by period supported by stability and microbiological evidence for this exact blend.
Dosing details
- Straightforward daily dosing approach for balanced peptide delivery.
- Daily Dose: 2,330 mcg (10 units / 0.10 mL) maintained throughout the 4-week cycle.
- Frequency: Once per day (subcutaneous), at a consistent time preferred.
- Cycle Length: 4 weeks of daily dosing, followed by 2–4 weeks off to evaluate progress and allow receptor resetting.
- Volume: Per-injection volume (~0.1 mL) is well below the 1.0–1.5 mL comfort threshold for subcutaneous administration.
- Syringe Recommendation: Use 0.3 mL (30-unit) insulin syringes for greater measurement precision at low volumes.
Storage
- Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions. Follow the specific product’s labeled storage conditions; no universal shelf life is established for this blend. Store in sealed container with desiccant if possible to prevent moisture absorption.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) at all times when not in use. Do not freeze reconstituted solution. Follow a use-by period supported for the exact formulation and handling conditions; bacteriostatic water alone does not establish potency or sterility.
- Allow frozen vials to reach room temperature before opening to prevent condensation.
- Protect reconstituted solution from light (store in amber vial or wrap in foil).
- Inspect solution before each use; discard if discolored, cloudy, or contains precipitate.
Administration technique
- Subcutaneous injection guidance based on clinical best practices.
- Clean the vial stopper and injection site with separate alcohol swabs; allow both to air-dry completely.
- Using an insulin syringe (typically 29–31 gauge, 5/16 to 1/2 inch needle), draw up the calculated dose (10 units = 0.1 mL).
- Select a site with adequate subcutaneous tissue (common sites include lower abdomen, thigh, or upper arm).
- Pinch a fold of skin; insert the needle at approximately a 45° angle into the fatty subcutaneous tissue. With short insulin needles, a 90° angle can also be used if injecting into a pinched skin fold.
- Inject slowly over 2–3 seconds; do not aspirate for subcutaneous injections.
- Withdraw needle and apply gentle pressure with a clean cotton swab; do not rub the injection site.
- Rotate sites systematically with each injection, maintaining at least 1–2 inches spacing between sites to prevent tissue irritation.
- Dispose of used syringes and needles immediately in a proper sharps container; never reuse needles.
Important notes
- Use new sterile insulin syringes for each injection; dispose in a sharps container immediately after use.
- Rotate injection sites systematically (abdomen, thighs, upper arms) at least 1–2 inches apart to reduce local irritation and prevent lipo-hypertrophy.
- Inject slowly over 2–3 seconds and wait a few seconds before withdrawing the needle to ensure complete delivery.
- Document daily dose, injection site, and any observations to maintain consistency and track progress.
- Practice aseptic technique at every injection: clean vial stopper and skin with separate alcohol swabs, allow to air-dry completely.
Protocol source: PeptideDosages.com
Common questions
Is GLOW the same as GHK-Cu?
No. GHK-Cu is one of three ingredients.
Do the ingredients work better together?
That has not been tested.
How long does GLOW take to work?
No reliable timeline exists for the blend.
Related in Skin and Hair
Sources and further reading (6)
- Badenhorst T, et al. GHK-Cu effects on collagen, elastin and wrinkle parameters. J Aging Sci, 2016.
- Staresinic M, et al. BPC 157 accelerates healing of rat Achilles tendon. J Orthop Res, 2003.
- Lee E, Burgess K. Safety of intravenous BPC-157 in humans: a pilot study, 2025.
- Ho ENM, et al. Doping control analysis of TB-500. J Chromatogr A, 2012.
- FDA. Bulk drug substances that may present significant safety risks.
- Source summary: PeptideDosages.com research overview (rewritten for NVO).
Laboratory research material: GLOW Research Use Only